Senators grilled Novo Nordisk CEO Lars Jorgensen at a hearing on Tuesday about the cost of diabetes drug Ozempic and weight loss medication Wegovy, both of which are often prohibitively expensive in the United States despite their life-saving potential.

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy, on Tuesday, Sen. Bernie Sanders alleged that 40,000 people a year in the US could die if the company doesn’t make the medicines more affordable.

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.